Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.
Celyad Oncology SA (CYAD) is a biotechnology company headquartered in Mont‑Saint‑Guibert, Belgium, with shares admitted to trading on Euronext. Its regulatory news flow provides detailed insight into the company’s strategic focus on managing and licensing its intellectual property portfolio, including proprietary technology platforms, as well as its capital structure and major shareholdings.
News about Celyad Oncology frequently covers decisions that affect its operational profile and financial position. For example, the company has announced the discontinuation of its research and development activities and a significant reduction in its R&D workforce due to limited cash resources, stating that it will concentrate on the management and licensing of its intellectual property portfolio. Other releases describe the divestiture of its research facility’s equipment and office furniture under an asset purchase agreement, which management expects to extend the company’s cash runway.
Investors following CYAD news can also track financing transactions and ownership changes. The company has reported a private placement financing with CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group, and has issued multiple transparency notifications detailing when this shareholder has crossed voting‑rights thresholds. In addition, Celyad Oncology regularly publishes updates on the total number of shares and voting rights, including the impact of double voting rights on certain registered shares.
This news page is useful for readers who want to monitor regulatory announcements on Celyad Oncology’s strategic decisions, capital increases, asset sales, major shareholdings and voting‑rights structure. By reviewing these updates, users can follow how the company’s focus on intellectual property, its financing arrangements and its ownership profile evolve over time.
Celyad Oncology (Euronext: CYAD) has secured a €1 million private placement through a subscription agreement with CFIP CLYD (UK) Limited (Fortress). The deal involves issuing 3,333,333 new ordinary shares at €0.30 per share, representing a 15% discount to the 10-day VWAP on Euronext Brussels.
Following the transaction, expected to close around August 5, 2025, Fortress will hold approximately 58.51% of the company's shares. The proceeds will support working capital and general corporate purposes, extending Celyad's cash runway from mid-Q3 2025 to mid-Q4 2025, providing additional time to evaluate strategic options for strengthening its balance sheet.
Celyad Oncology (NASDAQ:CYAD) has announced a comprehensive strategic review amid financial challenges. The company reported a treasury position of €4.2 million as of December 31, 2024, with cash runway only extending into Q3 2025. The review encompasses potential asset sales, restructuring, mergers, and financing options.
The company has already implemented cost-reduction measures, with R&D expenses decreasing to €3.2 million in 2024 (from €4.6 million in 2023) and G&A expenses reducing to €3.2 million (from €6.0 million in 2023). Celyad is currently in discussions for potential out-licensing deals on its CAR-T and shRNA platforms.
Celyad Oncology has reported its full year 2024 financial results, showing a net loss of €5.8 million (€0.14 per share), improved from €8.5 million loss in 2023. The company's treasury position stands at €4.2 million as of December 31, 2024.
Key operational highlights include advancement of their multiplex miRNA-based shRNA non-gene editing technology to a 5-plex system and development of multispecific NKG2D-based CAR T-cell platform. The company has also re-initiated manufacturing of C-Cath®, an intra-myocardial injection catheter.
Financial metrics show reduced R&D expenses at €3.2 million (down from €4.6 million in 2023) and G&A expenses at €3.2 million (down from €6.0 million). Net cash used in operations decreased significantly to €2.8 million from €15.2 million in 2023. The company projects its current cash position will fund operations into Q3 2025.
Celyad Oncology has published preclinical and clinical data for CYAD-211, their first allogeneic CAR T-cell therapy candidate, in the International Journal of Molecular Science. The study focused on patients with relapsed or refractory multiple myeloma.
The therapy utilizes a novel microRNA-based shRNA technology that interferes with CD3ζ expression in the T-cell receptor complex. Preclinical data demonstrated successful knockdown of CD3ζ and inhibition of TCR-mediated activation both in vitro and in vivo.
The Phase I IMMUNICY-1 clinical trial results showed an overall good safety profile with some clinical responses. Notably, no signs of graft-versus-host disease (GvHD) were observed, validating the technology's effectiveness in preventing this common complication. This non-gene edited approach offers advantages in implementation, safety, efficiency, and the ability to modulate multiple target genes simultaneously.
Celyad Oncology (Euronext: CYAD) announces two poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Houston, November 6-10, 2024. The first poster (Abstract 262) focuses on PSMA/NKG2DL tandem CAR T-cells to improve anti-tumor efficacy against prostate cancer, to be presented on November 9. The second poster (Abstract 1133) discusses efficient and safe modulation of multiple target genes in CAR T-cells using a miRNA-based shRNA platform, to be presented on November 8.
Both posters will be available in the poster hall and virtually to SITC Annual Meeting registrants from November 7 at 10 a.m. ET. The posters will also be archived on Celyad Oncology's website under the 'Scientific Publications' section.
Celyad Oncology (Euronext: CYAD) has appointed Matt Kane as its new Chief Executive Officer, effective October 1st, 2024. Kane brings over 20 years of experience in entrepreneurial, CEO, and board roles, with expertise in genome editing and allogeneic CAR T-cell therapies. His career highlights include:
- Raising over $500M in equity financings
- Forming partnerships valued at over $4B
- Co-founding Precision BioSciences (DTIL) in 2006
- Leading Precision's IPO and development of four allogeneic CAR T therapies
- Recent CEO role at Tune Therapeutics, an epigenetic editing company
Kane's appointment aligns with Celyad's focus on CAR T technology and ambitious plans for growth and development in the oncology space.
Celyad Oncology (CYAD) reported its H1 2024 financial results and business highlights. The company is focusing on research and development, particularly in intellectual property monetization. Key developments include:
1. Proof-of-concept for multiplex shRNA non-gene edited technology and multispecific NKG2D-based CAR T-cell platform.
2. Active participation in scientific conferences and publications in peer-reviewed journals.
3. Re-initiation of C-Cath® manufacturing and commercialization.
4. Cash runway extended until Q3 2025.
Financial highlights:
- R&D expenses: €1.5M (down from €2.1M in H1 2023)
- G&A expenses: €1.7M (down from €3.7M in H1 2023)
- Net loss: €3.0M (€0.07 per share)
- Cash position: €6.2M as of June 30, 2024
Summary not available.
Summary not available.
Summary not available.